ICIs use specific monoclonal antibodies (mabs), including anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) and/or anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4), to treat several cancers. This evidence concerns the gene CD274 and cancer.